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INTRODUCTION
1. INTRODUCTION
1.1 ORAL DRUG DELIVERY SYSTEMS
 Streubel et al., (2010) reported oral drug delivery has been known for decades
as the most widely utilized administered route among all the routes that have
been employed for dosage forms. The reasons that the oral route achieved such
popularity  due to it  is  safety,  convenience,  it  does  not  need assistance,  non
invasive, often painless, the medicament need not be sterile and also is cheaper.
Both solid dosage form as well as liquid dosage form given orally. The various
dosage forms administered orally, the tablet is one of the most preferred dosage
forms  because  of  its  ease  of  manufacturing,  convenience  in  administration,
accurate dosing,  stability compared with oral  liquids and because it  is  more
tamperproof than capsules
1.2 Immediate release dosage form
Rajpoot et al., (2011) develop the  immediate release solid oral dosage     forms
are  classified    as  either    having    rapid    or  slow dissolution rates.
Immediate release dosage forms are those for which ≥85% of labeled amount
dissolves within 30 min. For immediate release tablets, the only barrier to drug
release  is  simple  disintegration  or  erosion  stage,  which  is  generally
accomplished in less than one hour.
Oral route of drug administration is perhaps the most appealing route for the
delivery of drugs. Of the various dosage forms administered orally, the tablet is
one of the most preferred dosage forms. The bioavailability of drug is dependent
on in vivo disintegration, dissolution, and various physiological factors. 
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The gastrointestinal tract provides sufficient fluid to facilitate disintegration of
the dosage form and dissolution of the drug. The large surface area of gastric
mucosa favors the drug absorption. Therefore, the oral route has continued to be
the most appealing route for drug delivery despite the advancements made in
the new drug delivery systems. Banker and Anderson stated that at least 90% of
all drugs used to produce systemic effect are administered orally. 
Immediate release tablets have received much attention in recent years, as they
are  preferred  by  pediatrics  and  geriatric  patients.  Bioavailability  of  a  drug
depends in absorption of the drug, which is affected by solubility of the drug in
gastrointestinal  fluid  and  permeability  of  the  drug  across  gastrointestinal
membrane.  The  drugs  solubility  mainly  depends  on  physical  &  chemical
characteristics  of  the  drug.  However,  the  rate  of  drug  dissolution  is  greatly
influenced by disintegration of the tablet.
The disintegration test is an official test and hence a batch of tablet must meet
the stated requirements of disintegration. Disintegrants, an important excipients
of the tablet formulation, are always added to tablet to induce breakup of tablet
when it comes in contact with aqueous fluid and this process of desegregation
of  constituent  particles  before  the  drug  dissolution  occurs,  is  known  as
disintegration process and excipients which induce this process are known as
disintegrants.
The objectives behind addition of disintegrants are to increase surface area of
the  tablet  fragments  and  to  overcome  cohesive  forces  that  keep  particles
together in a tablet.
Ansel et al., (1999) An ideal dosage regimen in the drug therapy of any disease
is the one, which immediately attains the desired therapeutic concentration of
drug in plasma (or at the site of action) and maintains it constant for the entire
duration  treatment.  This  is  possible  through  administration  of  conventional
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dosage form in particular dose and at a particular frequency. Thus drug may be
administered by variety of routes in a variety of dosage form.
Martin et al., (2003) Drugs are more frequently taken by oral administration.
Although a few drugs taken are intended to be dissolved with in the mouth, the
vast majority of drugs taken are swallowed. Compared with alternate routes
the  oral  route  of  drug  administration  is  the  most  popular  and  has  been
successfully used for  the  conventional  delivery of  drug.  It  is  most  natural,
uncomplicated,  convenient,  safe  means  of  administering  drugs,  greater
flexibility in dosage form design, ease of production and low cost
1.3.TABLET
Gabrielsson et al., (2002) reported current market, tablet is most widely used
dosage form because of ease of administration and convenient for industry to
manufacturer.  In  pharmaceutical  industries,  manufacturing  of  tablets  are
usually focused on the optimization of the excipients mixture composition to
obtain a product that meet established standard.
Parmar (2009)The tablet  dosage form is  a  versatile  drug delivery system.
Different types of tablet formulations  are   available,   which   could   be
broadly  classified   based   on:   (1)   route   of   administration   such   as
tablets for oral delivery, sublingual delivery, buccal delivery, rectal delivery or
vaginal delivery, and (2) formulation characteristics such as immediate release
tablets, effervescent tablets, melt- in-mouth or fast dissolving tablets, delayed
release or extended release tablets. In all the cases, the general manufacturing
process,  machinery  used  for  preparation  of  tablets  and  materials  used  are
similar.
Dept. of pharmaceutics,  Arulmigu Kalasalingam College of Pharmacy 3
INTRODUCTION
1.4 DIRECT COMPRESSION:
Rane et al.,  (2009) Direct compression has taken the centre stage in tablet
manufacturing    because    the    process    avoids  many of  the  problems
associated with granulation  methods.   It    is    a   simple,    economical
process   and because     heat   or   moisture    is  not  required,    it  is suitable
for   unstable   compounds.   However,   the success      of  the   direct
compression       process      is  determined to a    greater  degree by the
excipients         chosen        because       they     impart      flow      and
compression   characteristics   to   the   powder   blend.  
Buwalda et al., (1997) Starch is a   versatile, cheap and readily available    as
found    wide    application     in   tableting    as  a  binder,      disintegrant,
diluent,     lubricant     and glidant. The native form of starch possesses poor
flow     and     compression       properties     making      it unsuitable       for
direct     compression.  researchers  have made  attempts  to  improve  on  the
flowability      and    compressibility       of   starch    by  modification       in
order   to  make    it  adaptable    for  direct compression. - 
NON STEROIDAL ANTI-INFLAMMATORY DRUGS
Non-steroidal inflammatory drugs usually abbreviated toNSAIDs these 
are a class of drugs that provide analgesic and antipyretic effects and in higher 
doses it produces anti-inflammatory effect. The term “non-steroidal” 
distinguishes these drugs from steroids
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CLASSIFICATION:
NSAID’s   can  be  classified  based  on  their  chemical  structure  or
mechanism of action older NSAIDs were known long before their mechanism
of  action  was  elucidated  and  were  for  this  reason  classified  by  chemical
structure or origin  newer substances are more often classified by mechanism of
action.
1) SALICYLATES
1) Aspirin (acetyl salicyclic acid)
2) Diflunisal
3) Salsalate
2) PROPIONIC ACID DERIVATIVES:
1) Ibuprofen
2) Dexibufrofen
3) Naproxen
3) Fenoprofen
4) Ketoprofen
5) Dexketoprofen
6) Flurbiprofen
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7) Loxoprofen
3) Acitic acid derivatives
1) Indomethacin
2) Sulidac
3) Ketrolac
4) Diclofenac
4) Enolic acid (Oxicam)derivatives
1) Piroxicam
2) Meloxicam
3) Droxicam
5) Fenamic acid derivatives (Fenamates)
1) Mefanamic acid
2) Meclofenamic acid
3) Flufenamic acid
4) Tolfenamic acid
6) Selective cox-2 inhibitors, Coxibs):
1) Celecoxib(FDA alert)
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2) Rofecoxib
3) Valdecoxib
4) Parecoxib
5) Firocoxib
7) Sulphanilamides
1) Nimesulide
8) Others
1) licofelone
2) Lysine clonixinate
9)Naturals:
1) Hyperforin
2) Figwort
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LITERATURE REVIEW
Martin et al., (1990)investigated lysine salt of  d,l-2-(4-isobutylphenyI)-
propionic acid (ibuprofen lysine) was administered as a single oral dose of 500
mg by means of commercially available coated tablets  Drug tolerability was
excellent  for  the  oral  administration  of  ibuprofen  lysine  as  well  as  for  the
intravenous  treatments  with  ibuprofen  free  acid.  Only  mild  and  transient
adverse  drug  reactions  such  as  mild  burning  or  dragging  sensation  during
injection or mild redness at the site of injection were reported.
Tadeuswz et al., (1993)  studied  lack of significant differences between
the AUC values from suppository and the intravenous studies with similar doses
implies complete absorption  of  ibuprofen from all the suppositories Ibuprofen
lysinate  was  absorbed  significantly  more  readily  than  the  free  acid  from
suppositories. The lysinate suppository with a lipophilic surfactant had a higher
absorption rate constant than that with a hydrophilic surfactant. The  ka values
did not  significantly differ  for  a  twofold difference in  dose.  Equations were
developed to calculate true AUC and area under the moment curve (AUMC)
values when A exceeds B, and to transform C versus t  plots to the origin with
A' = A = B.
Donald  et al.,  (1995) reported single-dose, double-blind, parallelgroup,
single-site study compared ibuprofen lysine 400 mg with acetaminophen 1000
mg and placebo in 240 patients with moderate-to-severe postoperative dental
pain.  The  relative  onset  of  analgesic  response,  overall  analgesic  efficacy,
duration  of  effect,  and safety  were  assessed  over  a  6-hour  postdose  period.
Analgesic efficacy was assessed by patient self-rating of pain intensity,  pain
relief, time to meaningful pain relief, need for additional analgesic medication,
and patient global evaluation. Ibuprofen lysine had a significantly faster onset of
action with greater peak and overall analgesic effect than did acetaminophen. 
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Inken  Stoye (1998)   studied    a  contribution  to  the  investigation  of
molecular  association  of  phospholipids  and amphiphilic  substances  like,  e.g.
non-steroidal  anti-inflammatory  drugs.  Our  research  focussed  on  physico-
chemical  characterization  of  ternary  systems  containing  ibuprofen  lysinate,
lecithin  and  water.  The  influence  of  the  resulting  microstructures  on  drug
release  and  permeation  through  excised  human  stratum  corneum  was  also
investigated..  A  special  emphasis  was  laid  upon  the  storage-induced
transformation of liposomal dispersions into mixed micellar solutions and its
influence  on  drug  release  and  permeation.  A model  for  the  transformation
process is presented Because of the association of ibuprofen lysinate molecules
with  phospholipid  molecules  within  the  liposomal  and  the  mixed  micellar
system the share of free ibuprofen lysinate monomers, which can pass through
the dialysis membrane in the release experiment, is markedly reduced. 
Glowka (2000)  Studies  were  performed  on  the  effect  of  ibuprofen
racemate ionization extent on the pharmacokinetics of its enantiomers following
administration in suppositories to rabbits. The suppositories, containing 146.3
mg  ibuprofen  in  acidic  form  (IBP)  or  250  mg  ibuprofen  lysinate  (IBPL),
equivalent to the above IBP dose, were prepared using lipophilic Witepsol H-15
as a base and administered to rabbits in a crossover design. Compared with IBP,
administration of IBPL was followed by faster absorption and elimination of R
and S enantiomers. However, significant differences at α = 0.05 were observed
only  at  the  stage  of  elimination.  AUC  was  markedly  higher  following
administration  of  suppositories  containing  IBP than  following  suppositories
with IBPL and this pertained to both R and S enantiomers..
Jörn Lötsch et al., (2001) investigated the pharmacokinetic equivalence
of two different formulations of ibuprofen lysinate with special focus on the
expected effects.Ibuprofen is one of the most frequently used over-the-counter
analgesics. Most commercial formulations come in tablets of 200 mg racemic
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ibuprofen. This contrasts with several reports that a dose of 400 mg racemic
ibuprofen is probably more appropriate to produce the desired analgesic effects .
It is therefore reasonable to develop ibuprofen formulations with tablet doses of
400  mg.  The  present  study  was  designed  to  compare  the  stereoselective
pharmacokinetics of such a newly developed 400 mg tablet formulation with
those of a standard formulation of 200 mg tablets. 
Matthias  et  al.,  (2005) studied  bioequivalence  between  a  400-mg
ibuprofen  extrudate  and  lysinate  formulation,  and  to  evaluate  the  relative
bioavailability of the extrudate tablet compared to a regular ibuprofen tablet,
based  on  Cmax and  AUC0-∞..  The  rate  of  absorption  at  fasted  state  was
considerably faster following administration of the ibuprofen extrudate and the
ibuprofen lysinate tablet than for regular ibuprofen. However, the overall extent
of absorption was not different, and a food effect could be demonstrated for all
3 formulations.
Jacob et al., (2007) Patent ductus arteriosus (PDA) is the failure of the
ductus that arises from the distal dorsal aortic arch to close during the first few
days  of  life.  The  treatment  options  for  PDA include  “watchful  waiting,”
pharmacologic  therapy  with  cyclooxygenase  (COX)  inhibitors  (COX-1  and
COX-2),  such  as  indomethacin  or  intravenous  (IV)  ibuprofen  lysine,  and
surgery when medical interventions have proved ineffective. The clinical trials
evaluating the utilization of IV ibuprofen lysine focus on either preventing the
persistence of a PDA or treating the PDA in premature infants in whom the
ductus  does  not  close  within  48  hours  of  birth.  Although  the  role  of  COX
inhibitors  in  prophylaxis  of  PDA has  been  studied,  it  has  not  been  clearly
delineated.  Treatment  of  PDA in  preterm low birth  weight  infants  from the
second day of life on with IV ibuprofen lysine has been studied in 4 major and 3
smaller clinical trials. Overall, in 7 studies with 492 patients, the closure rate of
PDA  was  75.1%  with  IV  ibuprofen  lysine  compared  to  73.5%  with
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indomethacin.  In  addition,  neonates  treated  with  IV  ibuprofen  lysine  had
significantly  better  creatinine  clearance,  urine  output,  serum creatinine,  and
blood urea nitrogen (BUN) profiles than indomethacin-treated patients. Overall,
IV ibuprofen lysine is as effective as indomethacin for closure of PDA, yet is
associated with a better  safety profile with fewer negative side effects when
compared to indomethacin.
Pai et al., (2008) Approximately 70-80% of newborns less than 28 weeks'
gestational age require pharmacologic and/or surgical  intervention to close a
hemodynamically significant patent ductus arteriosus (PDA). Indomethacin has
been  the  pharmacologic  treatment  of  choice  and  has  also  been  used
prophylactically  in  very  premature  neonates  to  prevent  PDA.  The  drug,
however, is associated with renal and gastrointestinal adverse effects. In July
2006, intravenous ibuprofen lysine became available in the United States for
treatment of hemodynamically significant PDA. The mechanism of action for
both indomethacin and ibuprofen lysine is through inhibition of prostaglandin
synthesis,  resulting  in  ductal  constriction.  Both  drugs  appear  to  be  equally
efficacious in closing echocardiographically confirmed PDA. Ibuprofen lysine
has demonstrated significantly less effects on cerebral,  renal,  and mesenteric
blood  flow  in  premature  neonates  when  compared  with  indomethacin.  A
transient but significant increase in serum creatinine concentration, decrease in
urine  output,  and  increase  in  frequency  of  oliguria  were  observed  with
indomethacin  when  compared  with  ibuprofen  lysine.  However,  the  rate  of
reopening of the ductus after pharmacologic closure and the need for rescue
therapy were not different between the two drugs. In addition, no differences
were noted in other outcomes such as frequency of intraventricular hemorrhage,
necrotizing  enterocolitis,  or  chronic  lung  disease,  as  well  as  in  duration  of
mechanical  ventilation  and  length  of  hospital  stay.  When  administered
prophylactically, ibuprofen lysine did not prevent intraventricular hemorrhage
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nor provide any neurodevelopmental benefits. In addition, ibuprofen lysine has
not been adequately studied in neonates of 27 weeks' gestational age or younger.
Ibuprofen lysine is as efficacious as indomethacin in treating hemodynamically
significant PDA in neonates greater than 27 weeks' gestational age.
Holt et al., (2008) To study the physical compatibility of ibuprofen lysine
injection  (NeoProfen,  Ovation  Pharmaceuticals  Inc.,  Deerfield,  IL)  with
medications  commonly  used  in  the  premature  neonatal  population  during
simulated  Y-site  administration.  Commonly  used  intravenous  medications  in
preterm infants were evaluated for physical compatibility with ibuprofen lysine
injection. A 20-mL sample of ibuprofen lysine drug product solution was mixed
with  a 20-mL sample  of  each  of  the  34  medications at  concentrations used
clinically. The mixtures were stored at room temperature and each sample was
evaluated for  turbidity and physical  appearance at  time 0 (immediately after
preparation) and at 4 hours after preparation.
Holt et al., (2008) To study the physical compatibility of ibuprofen lysine
injection  (NeoProfen,  Ovation  Pharmaceuticals  Inc.,  Deerfield,  IL)  with
medications  commonly  used  in  the  premature  neonatal  population  during
simulated  Y-site  administration.  Commonly  used  intravenous  medications  in
preterm infants were evaluated for physical compatibility with ibuprofen lysine
injection. A 20-mL sample of ibuprofen lysine drug product solution was mixed
with  a 20-mL sample  of  each  of  the  34  medications at  concentrations used
clinically. The mixtures were stored at room temperature and each sample was
evaluated for  turbidity and physical  appearance at  time 0 (immediately after
preparation) and at 4 hours after preparation.
Ambat et al., (2008) studied the influence of IBU on B–A binding was
measured by saturation index and horseradish peroxidase assays. B–A solutions
were prepared at B:A ratios of 0.5, 1.0, 1.5 and 2.0 and bilirubin concentrations
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of 5 and 10 mg per 100 ml. Drug concentrations used were 142.5, 200 and 285
mg l-1 for IBU and 100 and 200 mg l-1 for acetyl salicylic acid (ASA). Similar
tests were performed on premature newborn sera with bilirubin concentrations
of 5 to 10 mg per 100 ml.Displacement of bilirubin was demonstrated only at
high IBU concentration and high B:A ratio. However, free bilirubin levels were
not shown to increase with increasing IBU concentration
Sheffield  et  al.,  ((2009)  Ibuprofen  might  have  advantages  over
indomethacin,  when  used  to  effectuate  closure  of  a  neonate’s  patent  ductus
arteriosus (PDA). Several previous studies indicate that platelet plug formation
is impaired after administration of indomethacin, On the basis of our present
studies, we speculate that ibuprofen lysine administration to neonates with a
PDA, when used according to the manufacturer’s recommendations, has little
adverse effect on platelet plug formation. This information might be a factor to
consider when deciding whether to select indomethacin or ibuprofen for PDA
closure.
Luke et al., (2012) reported Prostaglandins are utilized to maintain the
patency  of  the  ductus  arteriosus  until  surgical  ligation  is  performed.  When
surgical  ligation  is  not  indicated,  prostaglandin  inhibitors.  Ibuprofen  was
initially thought to have less adverse effects, such as a decreased incidence of
oliguria, gastrointestinal (GI) toxicity, and cerebral hypoperfusion. The use of
ibuprofen has been shown to increase the incidence of pulmonary hypertension. 
Patrizia  Santi et  al., (2003)  studied   in  vitro  the  post-iontophoresis
transport of ibuprofen lysine across rabbit ear skin, from ibuprofen lysine water
solutions. The results showed a significantly higher cathodal transport compared
to passive flux. Anodal iontophoresis also increased ibuprofen permeation, even
though the drug is negatively charged. The application of an electric current for
a limited period of time, followed by passive diffusion from the reservoir in
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contact  with  the  skin,  produced  much  higher  post-iontophoresis  fluxes  of
ibuprofen than passive diffusion. 
Lambert et al.,  Template bleeding time before and at  various intervals
after ibuprofen lysine dosing of 20 neonatal intensive care unit (NICU) patients.
Each bleeding time measured is shown by an 'X'. Lines connect the bleeding
times  performed  before  the  first  dose  of  ibuprofen  with  those  performed at
various preset intervals following the dose.
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AIM
To develop a bioequivalent, robust, stable and cost effective formulation
of  immediate  release  ibuprofen  lysine  Tablets  342  &  684mg  equivalent  in
performance to Reference product by direct compression method.
Objective
The objective of the present study is to:
 To develop a formulation of immediate release tablets of ibuprofen lysine
of   strengths 342mg   and  684mg which  shall  be  bioequivalent  to
Reference product 342mg and 684mg respectively.
 To develop a best processing method using different grades of excipients.
 To develop and evaluate the in-vitro dissolution release of the prepared
tablets and to compare with the Reference product.
 To carry out the stability studies of the final formulated product as per the
ICH guidelines.
 Data characterization and compilation of the final formulated product.
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PLAN OF WORK
 Literature review
 Drug & excipient profile
 Preformulation Studies
• Evaluation of drug substances 
• Drug-Excipients Compatibility Studies 
• selection of compatible excipients.
 Materials and equipments used
 Formulation trails 
 Compression of immediate release tablets
• Direct Compression (DC grade)
Evaluation of innovator and test product
 Bulk density
 Particle size distribution
 Angle of repose
 Weight variation
 Thickness
 Hardness 
 Friability
 Disintegration
 Assay
 Dissolution
 Related Substances
Stability evaluation   
 Weight  variation,  Thickness,  Hardness,  Friability,  Dissolution  and
Disintegration.
 Assay and Related substance
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MATERIALS & METHODS
5.1 Materials used
The following materials are used for the formulation of Ibuprofen lysine
tablets
Table No 1: List  of  materials  used for  formulation of  Ibuprofen lysine
tablets
Sl.no
Name of the ingredients
Grade Function Source
1 Ibuprofen lysine USP Non steroidal anti
inflammatory agent
Shasun
2
Sodium starch glycollate USP/NF Tablet disintegrant.
DMV 
Fonterra 
Excipients
3 Povidone K30 Ph.Eur Binder Shasun
4 Magnesium stearate USP/NF Lubricant Nitika
5 Opadry white IH Film coating agent Colorcon 
6 Purified water USP Vehicle In house
EQUIPMENTS USED
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The following materials are used for the formulation Ibuprofen lysine Tablets
Table No: 2 List of equipments used for formulation Ibuprofen lysine
Tablets
S.No Equipments Manufacturer
1. Microscope Nikon
2. Digital Vernier Caliper North Lab
3. pH Meter Eutech 
4. Electronic Weighing Scale - 220 g, 320 g, Sartorious
5. Multicheck (Hardeness, Thickness and 
Dimension) Erweka
6. Friabilator Electrolab
7. Electromagnetic  Sieve shaker Electrolab
8. Tapped volumeter Erweka, Germany
9. Disintegrator Electrolab
10. Dissolution apparatus Electrolab, Mumbai
11. Mechanical Stirrer Remi, Mumbai
12. Hot air Oven Thermolab
13. Compression Machine -8 station Erweka
14. Coating machine - Conventional Ideal Cures
15. Induction sealer Sigma, Chennai
16. UV visible spectrophotometer Shimadzu,  Japan
17. HPLC Waters, Karnataka
18. Stability chamber- 40°C/75%RH Thermolab, Maharashtra
19. Stability chamber- 50°C/90%RH Thermolab, Maharashtra
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DRUG PROFILE
Name                              : Ibuprofen Lysine
Drug Class                     : Non steroidal anti-inflammatory drug 
BCS Class : Class I (High solubility and High Permeability)
Chemical Name : Lysine salt of 2(4-isobutylphenyl)propionic acid  or   
(2S)-2,6-diaminohexanoic acid; 2-[4-(2-methylpropyl)
phenyl] propanoic acid  
Chemical nature : Ibuprofen Lysinate is weakly Acid
Chemical structure:
Ionization at different pH:
S.No pH % of ionization
1 1 0
2 2 0
3 3 0
4 4 0
5 5 0
6 6 0
7 7 0
8 8 3
9 9 25
Site of absorption : unionized at all pH values; absorption takes place in
                                             entire GIT.
Molecular Formula : C13H18O2.C6H14N2O2 
Molecular weight : 352.48
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CAS No : 57469-76-8 
Physical Characterization:
a. Appearance:  White, crystalline powder or colourless crystals.
b. Solubility     : It is soluble in water (1%w/v), freely soluble in acetone,
in methanol and in methylene chloride. It dissolves in dilute solutions
of alkali hydroxides and  carbonates 
c. pH of 1 % W/V aqueous solution:  6.0 - 8.0
d. Melting point           :  178 - 182 °C
e. Polymorphism          : No polymorphism    
f. Chirality                    : one chiral centre and thus two stereoisomers 
exist.  
g. Lipophilicity characteristics (Log P): 3.97
    Mechanism of action:
Ibuprofen  lysine  is  the  lysine  salt  of  ibuprofen.  Ibuprofen  is  a
propionic acid derivative NSAID that has demonstrated its efficacy by
inhibition  of  prostaglandin  synthesis.  In  humans,  ibuprofen  reduces
inflammatory  pain,  swellings  and  fever.  Furthermore,  ibuprofen
reversibly inhibits platelet aggregation.
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Pharmacokinetic Parameters:
Absorption
Most  pharmacokinetic  data  obtained  following  the
administration  of  ibuprofen  acid  also  apply  to  ibuprofen
lysine. 
Ibuprofen  is  well  absorbed  from the  gastrointestinal  tract.
Ibuprofen  is  extensively  bound  to  plasma  proteins.  Peak
serum concentration occurs 1 - 2 hours after administration.
However,  ibuprofen  is  more  rapidly  absorbed  from  the
gastrointestinal  tract  following  the  administration  of
Ibuprofen  Lysine  400  mg  Tablets,  with  peak  serum
concentration  occurring  approximately  38  minutes  after
administration
Food 
Effects
Food does not affect the extent of absorption of Ibuprofen,
however, the maximum concentration (Cmax) is reduced and
the  time  to  maximum  concentration  (tmax)  is  prolonged  if
Ibuprofen is taken with food.
Distributio
n
Population Vd of racemic ibuprofen for premature infants at
birth is 320 mL/kg.
Metabolis
m and 
Distributio
n
Ibuprofen is metabolised in the liver to two major 
metabolites with primary excretion via the kidneys, either as 
such or as major conjugates, together with a negligible 
amount of unchanged ibuprofen. Excretion by the kidney is 
both rapid and complete. 
Eliminatio
n
Elimination half-life is approximately 2 hours. No significant
differences  in  pharmacokinetic  profile  are  observed  in  the
elderly. The t ½ in infants is more than 10 times longer than
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in adults.  Interindividual variability in Cl and Vd are 55%
and 14%, respectively
Indication:
• Aseptic Necrosis
• Back Pain
• Costochondritis
• Cystic Fibrosis
• Dysautonomia
• Fever
• Frozen Shoulder
• Gout, Acute
• Headache
• Muscle Pain
• Osteoarthritis
• Pain
• Patent Ductus Arteriosus
• Period Pain
• Rheumatoid Arthritis
• Sciatica
• Temporomandibular Joint 
Disorder
Overdose
Ibuprofen overdose has become common since it was licensed for OTC
use. Many overdose experiences are reported in the medical literature, although
the frequency of life-threatening complications from ibuprofen overdose is low.
Human response in cases of overdose ranges from absence of symptoms to fatal
outcome despite intensive-care treatment. Most symptoms are an excess of the
pharmacological  action  of  ibuprofen,  and  include  abdominal  pain,  nausea,
vomiting,  drowsiness,  dizziness,  headache,  tinnitus,  and  nystagmus.  Rarely,
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more severe symptoms, such as  gastrointestinal bleeding,  seizures,  metabolic
acidosis,  hyperkalaemia,  hypotension,  bradycardia,  tachycardia,  atrial
fibrillation, coma, hepatic dysfunction, acute renal failure, cyanosis, respiratory
depression, and  cardiac arrest have been reported. The severity of symptoms
varies  with  the  ingested  dose  and  the  time  elapsed;  however,  individual
sensitivity also plays an important role. Generally, the symptoms observed with
an overdose of ibuprofen are similar to the symptoms caused by overdoses of
other NSAIDs.
Adverse effects
Common  adverse  effects  include:  nausea,  dyspepsia,  gastrointestinal
ulceration/bleeding,  raised  liver  enzymes,  diarrhea,  constipation,  epistaxis,
headache, dizziness, priapism, rash, salt and fluid retention, and hypertension. A
study from 2010 has shown regular  use  of  NSAIDs was associated with an
increase in hearing loss. 
SODIUM STARCH GLYCOLATE
Nonproprietary Names
• BP: Sodium starch glycollate 
• PhEur: Carboxymethylamylum natricum
• USPNF: Sodium starch glycolate
Synonyms
Carboxy methyl starch, sodium salt; starch carboxy methyl ether, sodium salt; 
Chemical Name 
Sodium carboxy methyl starch 
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Functional Category
Tablet disintegrants.
Applications in Pharmaceutical Formulation or Technology
Sodium starch glycolate  is  used in  oral  pharmaceuticals  as  a  disintegrant  in
tablet formulations.
Description
Sodium starch glycolate is a white to off-white, odorless, tasteless, free-flowing
powder. Sparingly soluble in ethanol (95%) and practically insoluble in water.
Stability and Storage Conditions
It is stable and should be stored in a well-closed container in order to protect it
from wide variations of humidity and temperature, which may cause caking.
Incompatibilities
Sodium starch glycolate is incompatible with ascorbic acid. 
Safety
Sodium starch glycolate oral ingestion of large quantities may be harmful.
POVIDONE 
Nonproprietary Names
BP: Povidone
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JP: Povidone
PhEur: Povidonum 
USP: Povidone
Synonyms
poly  [1-(2-oxo-1-pyrrolidinyl)ethylene];  polyvidone;  polyvinylpyrrolidone;
PVP; 1-vinyl-2-pyrrolidinone polymer.
Chemical Name 
1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical Formula 
(C6H9NO) n 
Functional Category
Disintegrant, dissolution aid, suspending agent and tablet binder.
Applications in Pharmaceutical Formulation or Technology
In tableting, Povidone is used as binders in wet-granulation processes and as
coating agents.
Description
Povidone occurs as a fine, white to creamy-white colored, odorless or almost
odorless, hygroscopic powder and freely soluble in acids, chloroform, methanol,
and water practically insoluble in ether, hydrocarbons and mineral oil.
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Stability and Storage Conditions
The powder is hygroscopic; it should be stored in an airtight container in a cool,
dry place.
Incompatibilities
Povidone is compatible in solution with a wide range of inorganic salts, natural
and synthetic resins, and other chemicals. 
Safety
Povidone  may  be  regarded  as  nontoxic  since  it  is  not  absorbed  from  the
gastrointestinal tract or mucous membranes.
MAGNESIUM STEARATE
Nonproprietary Names
• BP: Magnesium stearate 
• JP: Magnesium stearate
• PhEur: Magnesii stearas 
• USPNF: Magnesium stearate
Synonyms
Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid, 
magnesium salt.
Chemical Name 
Octadecanoic acid magnesium salt 
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Empirical Formula 
C36H70MgO4
Functional Category
Tablet lubricant.
Applications in Pharmaceutical Formulation or Technology
Magnesium stearate is widely used as a lubricant.
Description
It is a very fine, light white, precipitated powder of low bulk density, having a
faint odor of stearic acid with a characteristic taste and greasy to the touch and
readily adheres to the skin. Practically insoluble in ethanol, ether and water;
slightly soluble in warm benzene.
Stability and Storage Conditions
Magnesium stearate is stable and should be stored in a well-closed container in 
a cool, dry place.
Incompatibilities
Incompatible  with  strong  acids,  alkalis,  iron  salts  and  strong  oxidizing
materials.
Safety
Oral consumption of large quantities may produce a laxative effect or mucosal
irritation.
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OPADRY WHITE 
Material description: 
White powder
Ingredients:
i. Titanium dioxide
ii. Polyethylene glycol/ Macrogol
iii. Hypromellose
iv. Elemental Iron content:0.0%
Table No: 3 Test of opadry white
S.N
o
Tests
Minimu
m
Maximu
m
Result
1. Ash,% 26.00 36.00 31.08
2. Colour difference 0.0 1.5 1.5
3. Appearance White powder
Application:  as a film coating agent for tablets.
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Preformulation studies: 
API Characterization
Pre-formulation  studies  were  performed  on  the  drug  which  includes
solubility, Bulk density, Tapped density, Compatibility. 
2 Solubility
Solubility is the property of a solid, liquid, or gaseous chemical substance
called solute to dissolve in a liquid solvent to form a homogeneous solution of
the  solute  of  the  solute  in  the  solvent.  The  solubility  of  a  substance
fundamentally  depends  on  the  used  solvent  as  well  as  on  temperature  and
pressure.  The  specified  quantity  of  sample  (1gm)  was  added  into  different
quantity  of  solvent  (methanol,  alcohol,  chloroform,  water,  acetone,  ethyl
acetate) in room temperature.
Bulk density:
Bulk density is  the ratio of the weight of  the powder to the bulk volume it
occupies. it is expressed in gm/ml. Weighed quantity of granules was transferred
into a 50 ml measuring cylinder without tapping, during transfer the volume
occupied  by  granules  was  measured.  Bulk  density  was  measured  by  using
formula.
P= m/Vo
      Where,
             Pi = Bulk density
             m = Mass of the blend, 
 Vo= Untapped Volume
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Tapped Density:
Weighed  quantity  of  granules  was  taken  into  graduated  cylinder,  volume
occupied by granules was noted down. Then cylinder was subjected to 500 taps
in  tapped  density  tester  (Electro  Lab  USP II),  the  % Volume variation  was
calculated by following formula.
 Pt = m/Vi
   Where,
            Pt = Tapped density
            M = Mass of the blend, 
Vi= Tapped volume
Carr’s compressibility index:
Compressibility  is  the  ability  of  powder  to  decrease  in  volume under
pressure.  Using  untapped  density  and  tapped  density  the  percentage
compressibility  of  granules  were  determined,  which  is  given  as  Carr’s
compressibility index. 
CI=Vi-V0 / Vi × 100
Where, 
    CI     = Compressibility index            
    Vo   = Bulk density 
     Vi = Tapped density  
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Table: 4 Compressibility index
Hausner’s Ratio:
It is measurement of frictional resistance of the drug. It was determined by the
ratio of tapped density and bulk density. 
Hausner’s Ratio = Vo/Vi
Where, 
Vo = Bulk density 
Vi  = Tapped density                    
Table No: 5 Hausner’s ratio
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(%)
Flow characters
<   10            Excellent
11-15            Good
16-20            Fair
21-25            Possible
26-31            Poor
> 32            Very poor
Flow characters Hausner’s ratio
Excellent 1.11
Good 1.12 – 1.18
Fair 1.19 – 1.25
Possible 1.26 – 1.34
Poor 1.35 – 1.45
Very poor 1.46 – 1.59
Very Very poor >1.60
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Physical Appearance:
The API was observed for its colour and physical state
Particle size distribution (PSD):
PSD is determined by stacking the sieves on top of one another in ascending
degree of coarseness (#20, #40, #60, #80, #100) and then placing the 100 g of
test sample on the top sieve (20#).The nest of sieves is subjected to 10 minutes
period of  agitation and then the weight  retained on each sieve is accurately
determined and expressed in terms of percentage
Drug excipients compatibility studies by HPLC
The successful formulation of a stable and effective solid dosage form depends
on the careful selection of the excipients that are added. The commonly used
excipients  are  mixed  with  the  API  in  the  different  ratios  and  subjected  to
accelerated condition (3 months in 40°C / 75 % RH) and at stress condition (1
month in 50°C / 90 % RH) the sample are monitored for any change in physical
state,  colour,  odour,  loss  on  drying  and  related  substances.  Any  excipients
contributing to such a change shall not be used in the formulation.
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Selection of excipients
Excipients are selected based on the excipients of reference product  apart from
the reference product, other excipients are selected based on the possible use of
them.
Stability study:
Sample preparation
The  mixtures of the drug and excipients are prepared by placing the accurately
weighed  amounts  of  the  drug  and  excipients  in  polybag  and  mixed  till
homogenous mixture is achieved. Then these mixtures are filled in vials and
closed with bromo butyl rubber stoppers & crimped with tear off clear lacquer
aluminum seals. These samples are charged at 50°C/90% RH and 40°C/75%
RH conditions.
Table No: 6  Storage condition and sampling interval
S.N
O
Storage condition Samples
packed in
Sampling
interval
1  Accelerated
condition 
( 40°C/75% RH)
Type  1  glass
vials 
1M,  2M  and
3M
2 Stressed condition
( 50 C/90% RH )
Type  1  glass
vials
I5  days  and
1M
Formulation development:
The development was started with direct compression process using the 
directly compressible grade excipients.
Direct compression
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Figure No: 1 Process Flow Diagram of direct compression
Dept. of pharmaceutics,  Arulmigu Kalasalingam College of Pharmacy 34
Weighing 
Drug substance in #40 mesh
Excipients in #40 mesh Sieving
Lubricant in #60 meshBlending & Lubrication 
Compression
Coating 
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Formulation trials by direct compression technique Procedure for direct 
compression process   
1.The desired quantities were weighed & dispensed.
2. Drug substance and Excipients were sifted through #40mesh, Magnesium 
stearate was sifted through #60mesh.
3. Drug substance with excipients was blended in polybagfor 5 min.
4. Lubricant were added in polybagwith the above blend and blended for 3 
min.
5. Evaluations of blend.
6. The blend was compressed in the 8-station compression machine Erweka 
TR-D8 with suitable toolings.
7. Evaluation of tablets.
Dept. of pharmaceutics,  Arulmigu Kalasalingam College of Pharmacy 35
EXPERIMENTAL INVESTIGATIONS
Table No:7  Composition of ibuprofen lysine 342mg strength (F1,F2,F3, F4,
F5 and F6 trials)
Ingredients
(mg/tab)
Mg/tablet
F1 F2 F3 F4
F5
(Reproducibi
lity Batch)
F6
(Scale
up
batch)
Ibuprofen 
lysine 
342 342 342
342
342
342
Povidone K 30 7 17 10 10.000 10 10
Sodium starch 
glycolate
25 25 36
31.000
31
31
Magnesium  
stearate
6 6 7
12.000
12
12
Core tablet 
weight (mg)
370 380 395
395
395
395
Opadry white * * * 11.85 11.85 11.85
Purified Water * * * q.s q.s q.s
Total weight 
(mg)
* * * 406.85
406.85
406.85
Batch size 750g
m
750
gm
750 gm 750gm
1500gm
3000g
m
Table No: 8 Composition of ibuprofen lysine 684mg strength (F7, F8, F9 
and F10 trials)
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Ingredients
(mg/tab)
Mg/tablet
F7 F8
F9
(Reproducibility
Batch)
F10
(Scale up
batch)
Ibuprofen lysine 684 684 684 684
Povidone K 30 30 20 20 20
Sodium starch 
glycolate
55
62.00
0 62.000 62.000
Magnesium  
stearate
21
24.00
0 24.000 24.000
Core tablet weight 
(mg)
790
790 790 790
Opadry white * 23.7 23.7 23.7
Purified Water * q.s q.s q.s
Total weight (mg) * 813.7 813.7 813.7
Batch size 750gm 750g
m
1500gm
3000gm
Manufacturing process – Direct compression
The  following steps are involved in the manufacturing of ibuprofen lysine 
tablets
1. Dispensing of all ingredients
2. Sifting of all ingredients
3. Blending 
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4. Compression
5. Coating
1.Dispensing :
In  this step the API and other excipients were dispensed as per the 
quantity mentioned table. The API and all excipient were taken in 
individual self seal cover.
2.Shifting:
• Ibuprofen lysine & povidone were co-sifted through #40mesh
• Sodium starch glycollate were passed through # 40 mesh.
• Magnesium stearate passed through the # 60 mesh.
3.Blending:
Equipment : V. Blender
Process :
• Ibuprofen lysine , povidone k30 and  Sodium starch glycollate were 
loaded  inV.blender for 5 minutes at slow speed.
• Magnesium stearate is added for 3 minutes at slow speed
4.Compression
Make :Erweka TR-D8 (8 Station)
Punch description For 342mg For 684mg
Dimension   14.4 × 8.7 mm 19 × 8.7
Upper punch   plain
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Lower punch  plain
5.Coating:
Table No:  Coating parameters for ibuprofen lysine  Tablets 25mg
S.N
o
Parameters Set parameters
1 Nozzle diameter of spray gun 1.0 mm
2
Distance between the tablet bed and spray 
nozzle 
15 cm
3 Peristaltic pump 1.0 RPM
4 Tablet bed temperature 41oC - 43oC
5 Inlet air temperature 65oC
6 Atomizing air pressure 2.0 Kg/cm
2
7 RPM of the coating pan 10-20 RPM
Preparation of Film coating solution:
       The film coating solution was prepared by simple solution method. It was
prepared by opadry white (Polyvinyl alcohol, Titanium dioxide, polyethylene
glycol  and Talc.)  dissolved in  weighed quantity  of  purified  water.  This  was
stirred for 45 minutes until get a uniform mixture was obtained. Then it was
sifted through #100 screen and used for coating of core tablets.
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Coating procedure: 
The compressed tablets were loaded in pan, and start to dry warming for 15
mins at  slow speed. Then take 50 numbers  of  warmed tablets,  and note
down the average weight of the tablets. Solid dispersion is 12% and coating
is done until tablets attain weight build up is 3%.
Evaluation of tablets 
Evaluation of physical characteristics :
     The formulated tablets were evaluated for the following physicochemical
parameters,
Thickness:
     Thickness mainly depends on die filling, physical properties of material to be
compressed under compression force. There is bound to be a small variation in
the thickness of individual tablet in a batch. But it should not be apparent to the
unaided  eye.  The  thickness  and  diameter  were  measured  by  using  vernier
calipers. 
Hardness:
    Tablet  requires  certain  amount  of  strength  or  hardness,  measured  by
Monsanto  hardness  tester.  Ten  tablets  were  randomly  picked  from  each
formulation and evaluated for hardness during manufacturing and is expressed
in N.
Friability:
  Friability  was  performed  by  using  Roche  friabilator,  normally  pre
weighed ten tablets were placed in the plastic chamber of friabilator. This was
then  operated  for  100  revolutions.  Tablets  dropping  from a  distance  of  six
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inches with each revolution.  Tablets are then dusted and reweighed. Loss of
less than 1% in weight is considered to be  acceptable.
                 F(%)   =    
Initial wt .Finalweigh t
Initialwt      
Weight variation test:
Twenty  tablets  were  selected  randomly  and  weighed  individually.  Calculate
average weight and compare the individual tablet weight to the average. Not
more than two of the individual weights deviate from the average weight by
more than the percentage shown in table and none deviate by more than twice
the percentage.
Disintegration test:
      The disintegration time was measured by using usp disintegration test
apparatus six tablets were placed  in the tube and the basket was kept in 1 litre
beaker of purified water maintained at 37 0C the basket containing tablets move
up and down through a  distance of 5 to 6cm at a frequency of 28 to 32 cycles
per minute .the specific time tablet is disintegrate completely was noted.
Dissolution studies:
Dissolution by HPLC:
Reagents/chemicals:
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Potassium  dihydrogen
orthophosphate
: AR Grade
Acetonitrile : HPLC Grade
Glacial acetic acid : AR Grade
Sodium hydroxide : AR Grade
Triethylamine : AR Grade
Water : Purified water/ Milli-Q /HPLC water
Dissolution Medium Preparation:
Dissolve 68.0 g of potassium dihydrogen orthophosphate and 9.0 g of sodium
hydroxide in 10000 mL of purified water and mix. Check and adjust to the pH
to 6.8 ± 0.05
Dissolution Parameters:
Apparatus : USP Type II (Paddle)
Medium  : pH 6.8 Phosphate buffer
Volume             : 900 mL
Rotational speed         : 50 RPM 
Temperature : 37.0 ± 0.5°C
Time                            : 5, 10, 15, 20, 30, 45 & 60 minutes or as required.
Preparation of mobile phase:
Mix 600 mL of acetonitrile, 400 mL of HPLC water, 1mL of glacial acetic acid
and 0.2 mL of triethylamine, filter through 0.45µm membrane filter and degas.
Chromatographic conditions: 
Dept. of pharmaceutics,  Arulmigu Kalasalingam College of Pharmacy 42
EXPERIMENTAL INVESTIGATIONS
Column : Hypersil BDS C18 150 x 4.6 mm, 5 µm
Flow rate : 1.0 mL/min
Column temperature : Ambient
Wavelength : 220 nm
Injection volume : 5 µL
Pump mode : Isocratic
Run time : 12 minutes
Preparation of solutions:
Preparation of standard solution for 342 mg: 
Weigh  accurately  about  47.5  mg  of  Ibuprofen  Lysine  reference/working
standard into a 25 mL volumetric flask. add 10 mL of water and sonicate to
dissolve and make up the volume up to the mark with water and mix. 
Then  dilute  5  mL of  solution  to  25  mL volumetric  flask  with  dissolution
medium (380 µg/mL of Ibuprofen Lysine). 
Preparation of standard solution for 684 mg: 
Weigh  accurately  about  47.5  mg  of  Ibuprofen  Lysine  reference/working
standard into a 25 mL volumetric flask. add 10 mL of water and sonicate to
dissolve and make up the volume up to the mark with water and mix. 
Then  dilute  10  mL of  solution  to  25  mL volumetric  flask  with  dissolution
medium (760 µg/mL of Ibuprofen Lysine). 
Preparation of sample solution:
Set the parameters of dissolution apparatus as per test method procedure. Place
previously weighed six tablets in each of the six dissolution vessels and start the
dissolution test. At the end of specified time, withdraw the sample from each of
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EXPERIMENTAL INVESTIGATIONS
the  dissolution  vessel.  Filter  the  solution  through 0.45  µm nylon membrane
filter discarding the first few mL of filtrate.
Procedure: 
Inject the following solutions and record the chromatogram. The retention time 
of Ibuprofen Lysine is about 4.9 minutes.
Table No: 9
S.
No
Solutions No. of
Injections
1 Blank (dissolution medium) 1
2 Standard solution 1
4 Sample solution 1
  
Evaluation of system suitability: 
1. The relative standard deviation for five replicate standard 2 areas should not 
be more   
     than 2.0%
      2. The tailing factor for Ibuprofen Lysine peak should not be more than 2.0.
3. The theoretical plates for Ibuprofen Lysine peak should not be less than 5000.
Calculation:
1. Similarity factor:
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2. % Drug release:
For 342 mg:
                             Asam        Std Wt.       5          900          P
% drug release       =     --------- x ---------- x --------x ---------x ------- x 100
                             Astd            25            25         LC         100        
Where,
Asam      : Area of Ibuprofen Lysine peak in the sample chromatogram
AStd          :  Average  area  of  Ibuprofen  Lysine peak in  the  standard  -2
chromatogram 
Std Wt.    : Weight of Ibuprofen Lysine reference / working standard taken in
mg
LC           : Label claim in mg
  P            : Percentage potency of Ibuprofen Lysine reference / working standard
on as is basis
For 684 mg:
                             Asam        Std Wt.      10          900          P
% drug release       =     --------- x ---------- x --------x ---------x ------- x 100
                             Astd            25            25         LC         100        
Where,
Asam      : Area of Ibuprofen Lysine peak in the sample chromatogram
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AStd          :  Average  area  of  Ibuprofen  Lysine peak in  the  standard  -2
chromatogram 
Std Wt.    : Weight of Ibuprofen Lysine reference / working standard taken in
mg
LC           : Label claim in mg
  P            : Percentage potency of Ibuprofen Lysine reference / working standard
on as is basis
Content uniformity:
Assay by HPLC:
Reagents/Chemicals:
Mono chloro Acetic acid  : AR grade
Ammonium Hydroxide : GR grade
Acetonitrile : HPLC grade
Water : HPLC grade
Chromatographic conditions:
Column : Hypersil ODS, 150x4.6mm, 5µm
Part No : 30105-154630
Column oven temperature              : 25°C
Flow rate : 1.0ml/min
Injection volume : 5.0µL
Wavelength : 220nm
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Run time : 10 minutes
Pump mode : Isocratic
Preparation of mobile phase:
Dissolve 4.0g of mono chloro acetic acid in 400ml of water and adjust the  pH 
to 3.00 ± 0.05 with ammonium hydroxide. Add 600ml of acetonitrile filter and 
degas.
Diluent:
Mixed water and acetonitrile in the ratio of 50:50%v/v.
Preparation of solutions:
Standard solution
Weigh  accurately  about  50.0  mg  of  Ibuprofen  Lysine  In-house  reference
standard into a 50 ml volumetric flask, add 30 ml of diluents and sonicate to
dissolve and make up the volume up to the mark with diluents and mix.
Then  dilute  5  ml  of  solution  to  50ml  volumetric  flask  with  diluent  (Conc:
100ppm)
Sample preparation:
Weigh 20 tablets and crush in a mortar to get a find powder. Accurately weigh
and  transfer powder equivalent to 500mg of Ibuprofen Lysine into a 250ml
volumetric flask. Add about 125ml of water and sonicate for 10 minutes with
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intermittent shaking, add about 75 ml of acetonitrile and sonicae for 20 minutes,
cool the solution to room temperature and make the volume up to the mark with
acetonitrile and mix. Filter the solution through 0.45µm nylon filter. Dilute 5ml
of the filtrate to 100ml volumetric flask with diluent (Conc: 100ppm).
Procedure:
Inject the blank, standard and sample solution in the sequence as given in the 
below table
Table No: 10
S.No
.
Solution No of Injections
1 Blank 1
2 Standard solution-1 1
3 Sample solution 2
Calculations:
Calculate the % content of Ibuprofen Lysine in the tablets by using the 
following Formula
     AT         Ws           5          250        100         Avg.wt
=          -------- x-------- x -------- x -------- x -------- x ------------- x P
              AS          50           50          Wt            5             LC
Where,
AT = Average area of Ibuprofen Lysine in the chromatogram of     
                        sample  solution.
AS = Average area of Ibuprofen Lysine in the chromatogram standard 
                        solution-2
Ws  = Weight in mg of Ibuprofen Lysine In-house reference standard
Wt = Weight of sample taken in mg
Avg.wt  = Average weight in mg
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LC = Label claim in mg
P = % Purity of Ibuprofen Lysine In-house reference standard
 Stability studies:
         As per in vitro release formulation F6, F10 was found to be desirable than
other formulation. Hence it was chosen for stability studies. The tablets were
packed  in  PVC/PVDC  blisters  and  kept  for  15  days  and  1  month  at
50ºC/90%RH and for 1M, 2M and 3M at 40C/75%RH in a stability chamber at
the  interval  of  mentioned  period,  tablets  were  withdrawn and  evaluated  for
physical properties like weight variation, thickness, hardness, and invitro drug
release was also carried out.
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 RESULTS AND DISCUSSION
Table No:11 Evaluation of RLD
S.No. TESTS
LIMITS
342 mg 684 mg
1 Description Almost white colored, film coated, caplet 
shaped tablets and printed NMP on one side
2
Identification 
A) By HPLC
The retention time of ibuprofen lysine peak 
obtained from the chromatogram of sample 
preparation corresponds to that of the 
chromatogram of similar preparation of 
standard as obtained in the assay. 
3 Average wt in (mg) 403.31 817.93
4 Average thickness (in mm) Minimum 4.55 – 
maximum 4.69
Minimum 6.51 – 
maximum 6.69
5 Disintegration test Minimum7.50 – 
maximum 8.36
Minimum10.20 – 
maximum 13.01
6  water content by KF (% w/w) 1.39 1.44
7  Assay by HPLC on dried basis (% 
w/w) 97.8 100.1
8  Dissolution   ( % amount of drug dissolved in 45 mins)
Minimum 103 – 
maximum 106
Average-105
Minimum 99– 
maximum 104
Average-102
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9
 Related substances by HPLC(% w/w)
2-[3-(2-methylpropyl) phenyl] 
propanoic 
Acid (impurity A)
2-(-n-butylphenyl) propionic acid 
(impurity B)
(2RS)-2-hydroxy-2-[4-(2- methyl 
propyl) phenyl] propanoic acid.
0.02
0.01
0.02
0.03
0.01
0.06
10 Highest unknown 0.02 0.02
11 Total  impurities 0.08 0.12
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Reference product Details
Table No: 12
Brand name Ibuprofen Lysine Tablets
Manufacturer / 
distributor
Reckitt Benckiser Healthcare (UK) Ltd /
Crookes Healthcare Limited
Strengths available 342mg and 684mg
RLD strength 684 mg
684mg Opaque, white with N684 mark on one face.
342mg Opaque, white with an identifying logo in black on one face.
Composition Ibuprofen Lysine 684/342 mg/tablet (equivalent to 400/200 mg Ibuprofen)
1 Povidone
2 Sodium starch glycolate
3 Magnesium stearate
4 Hypromellose
5 Talc
6 Opaspray White M-1-7111B (contains hypromellose and Titanium 
dioxide (E171))
7
Opacode Black S-1-8152HV (contains “black” iron oxide (E172), 
shellac, soya lecithin and Antifoam DC 1510).
Packing details
The blisters are packed in cardboard cartons. Pack sizes: 4, 6, 
8,12,16 and 24 tablets
684mg
342mg
Storage condition Do not store above 30ºC. Store tablets in the original packaging.
DRUG-EXCIPIENTS COMPATIBILITY STUDY
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Table No: 13 Drug-Excipient Compatibility Chart
Drug:
Excipients
proportion
Ratio Stability Condition Imp A(%)
Imp B
(%)
Imp C
(%)
Imp D
(%)
Unknown
Imp E
(%)
Total
Impurity
(%)
API -
INITIAL ND ND ND 0.02 ND 0.05
40°C/75%RH-1M ND ND ND 0.02 ND 0.04
40°C/75%RH-2M ND ND 0.01 0.03 0.01 0.04
40°C/75%RH-3M ND ND 0.01 0.03 ND 0.06
50°C/90%RH-1M ND ND ND 0.02 ND 0.06
API+
Povidone K
30
1:1
INITIAL ND ND 0.01 0.02 ND 0.05
40°C/75%RH-1M ND ND 0.01 0.02 ND 0.04
40°C/75%RH-2M ND ND 0.01 0.03 ND 0.07
40°C/75%RH-3M ND ND 0.01 0.02 0.02 0.16
50°C/90%RH-1M ND ND ND 0.02 ND 0.06
API+ Sodium
starch
glycolate
1:1
INITIAL ND ND 0.01 0.03 ND 0.05
40°C/75%RH-1M ND ND ND 0.02 ND 0.04
40°C/75%RH-2M 0.01 ND 0.01 0.03 ND 0.07
40°C/75%RH-3M ND ND 0.01 0.02 0.02 0.16
50°C/90%RH-1M 0.01 ND ND 0.02 ND 0.06
API+
Magnesium
stearate
1:1
INITIAL ND ND 0.01 0.03 ND 0.05
40°C/75%RH-1M ND ND 0.01 0.02 0.01 0.05
40°C/75%RH-2M ND ND 0.01 0.03 ND 0.05
40°C/75%RH-3M ND ND 0.01 0.03 ND 0.06
50°C/90%RH-1M ND ND ND 0.02 ND 0.03
API+Povidone 
K 30
+ Sodium starch
glycolate
+ Magnesium
stearate
 
mixture
INITIAL ND ND ND 0.02 ND 0.04
40°C/75%RH-1M ND ND 0.01 0.03 ND 0.05
40°C/75%RH-2M ND ND 0.01 0.03 ND 0.06
40°C/75%RH-3M ND ND 0.01 0.03 ND 0.06
50°C/90%RH-1M ND ND 0.01 0.03 ND 0.06
Povidone K 30
+ Sodium starch
glycolate
+ Magnesium
stearate
mixture
INITIAL ND ND 0.01 0.03 ND 0.05
40°C/75%RH-1M ND ND 0.01 0.02 0.01 0.04
40°C/75%RH-2M ND ND 0.01 0.03 ND 0.05
40°C/75%RH-3M ND ND 0.01 0.03 ND 0.06
50°C/90%RH-1M ND ND ND 0.02 ND 0.03
API+
Opadry II
White
1:1
INITIAL ND ND 0.01 0.03 ND 0.05
40°C/75%RH-1M ND ND ND 0.02 0.01 0.04
40°C/75%RH-2M ND ND ND 0.02 0.01 0.05
40°C/75%RH-3M ND ND 0.01 0.03 ND 0.06
50°C/90%RH-1M ND ND ND 0.02 ND 0.03
Table No: 14 Impurities and Limits
IMPURITIES LIMITS
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Impurity A Not more than 0.15%
Impurity B Not more than 0.15%
Impurity C Not more than 0.15%
Impurity D Not more than 0.15%
Impurity E Not more than 0.10%
Total impurities Not more than 0.5%
Observation and Conclusion
All the excipients used in the Drug-Excipients compatibility study were found to be compatible
and the Impurities were within the limits. Hence further formulation development studies are
proceeded.
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DISSOLUTION PROFILE OF REFERENCE PRODUCTS 
Ibuprufen lysine is not published in any of the official  monograph and hence to analyze and
confirm  the  Reference  products dissolution  characters,  the  both  strengths  of  the Reference
products tablets are analyzed in 3 different Media.
I. Dissolution profiles in Reference products Purified water
Table No: 15 Dissolution profiles of the Reference products in Purified water
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ± 0.5˚C
Volume 900 ml
Media Purified water
Method: HPLC
Time in
minutes
% Drug Release in Purified water
342 mg 684 mg
5 42 27
10 92 72
15 100 90
20 104 95
30 102 99
45 103 96
60 107 98
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Figure No: 2 Dissolution graph of the Reference products in Purified water
II. Dissolution profiles in 0.1N HCl
Table No: 16 Dissolution profiles of the Reference products in 0.1N HCl
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Type USP Type - II (Paddle)
RPM 50
Temp 37oC ±  0.5˚C
Volume 900 ml
Media 0.1N HCl
Method: HPLC
% Drug 
Release in 
0.1N HCl
Time in
minutes
342 mg
26 27
10 78 72
15 96 89
20 99 94
30 101 100
45 101 98
60 101 98
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III.  Dissolution profiles in pH 6.8 Buffer
Table No: 17 Dissolution profiles of the Reference products in pH 6.8 Buffer
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ±
0.5˚C
Volume 900 ml
Media pH 6.8 Buffer
Method: HPLC
Time in
minutes
% Drug Release in pH 6.8 Buffer
342mg 684 mg
5 44 22
10 86 63
15 95 85
20 97 90
30 98 99
45 98 101
60 99 91
Figure No: 4 Dissolution graph of the Reference product in pH 4.5 Buffer
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Observation and disscusion
The two strength released ≥ 85% of the drug with in 15 minutes in Purified water, 0.1N 
HCl and pH 6.5 Buffer. The dissolution profile results obtained in the 3 media for the two strength are 
kept as the standard reference for the evaluation in further dissolution studies.
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EVALUATION OF FORMULATION TRIALS
DIRECT COMPRESSION
Ibuprofen lysine Tablets 342mg 
Table No: 18 Characteristics of the Formulation trial–F1 blend
S.No Parameters Results
1 Description/Appearance White coloured powder blend
2 Bulk density (g/ml) 0.50
3 Tapped density (g/ml) 0.68
4 Carr’s Index (%) 26
5 Hausner’s Ratio 1.36
6 Flow property Poor
Observation
The Carr’s index and the Hausner’s Ratio indicated that the blend has poor flow characters. To
understand the powder behaviour the batch was taken further for compression.
It  was observed  that  the blend had formed a cake  in  the feed  frame and there  were  weight
variations due to non uniformity of the powder flow. 
disscusion
It was plan to increase the binder concentration for the better compressibility
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Ibuprofen lysine Tablets 342mg strengths
Table No: 19 Characteristics of the Formulation trial–F2 blend
Observation:
The Carr’s index and the Hausner’s Ratio indicated that the blend has Passable
flow characters. 
It was observed that the blend had formed rat hole and chocked in the feed frame
and there were weight variations due to non uniformity of the powder flow.
Hardness was high but Disintegration was more than 16mts
Discussion:
It was planned to decrease the binder concentration for lesser Disintegration time
and to addition of lubricants for overcome the rat hole.
.
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S.No Parameters Results
1 Description/Appearance White coloured powder blend
2 Bulk density (g/ml) 0.55
3 Tapped density (g/ml)
0.62
4 Carr’s Index (%)
11.290
5 Hausner’s Ratio
1.127
6 Flow property Possible
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Ibuprufen lysine Tablets 342mg 
Table No: 20 Characteristics of the Formulation trial–F3, F4, F5 & F6 blend
S.No PARAMETERS F3 F4
F5
(Reproduci
bility
batch)
F6 (scale
up batch)
1. Bulk density (g/ml) 0.47 0.45 0.44 0.45
2. Tapped density (g/ml) 0.59 0.56 0.56 0.56
3. Carr’s index (%) 20.34 19.64 21.42 19.64
4. Hausner’s ratio 1.26 1.24 1.27 1.24
5. Flow property Passable Fair Passable Fair
Particle size distribution
Sieve Analysis
Cumulative % Retained
F3 F4 F5 Finalized batch
1. # 40 mesh retention 37.00 33.00 35.00 34.00
2. # 60 mesh retention 57.00 51.00 52.00 51.00
3. # 80 mesh retention 69.00 67.00 66.00 66.00
4. # 100 mesh retention 79.00 76.00 75.00 76.00
5. # PAN 100.00 100.00 100.00 100.00
Observation and Conclusion
Among the formulation trials ,F3 were found to be slightly coarser in nature. The remaining
trials showed comparative reproducibility.
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CORE TABLETS
S.No PARAMETERS F3 F4
F5
(Reproduc
ibility
batch)
F6 (scale
up batch)
1. Average Weight (mg) 387.85 386.89 385.40 386.33
2. Thickness (mm) 3.39 3.41 5.50 3.57
3. Hardness (N) 122 128 133 136
4. Friability (% w/w) 0.06% 0.02% 0.02% 0.02%
5.
Disintegration Time 
(min & sec)
3 min
20sec
6min15sec-
6mins 50 sec
6min 20sec-
6mins 58 sec
6mins 31
sec- 6 mins
46sec
COATED TABLETS
6 Thickness(mm) - 4.51 4.55 4.60
7
Disintegration time 
(min & sec) -
7min05sec 7min 20sec-
7mins 58 sec
7mins 31
sec- 7mins
46sec
Table No: 21 Parameters of the Formulation trial – F3, F4, F5 & F6
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DISSOLUTION PROFILE
Formulation trial- F3
Table No: 22 Comparative Dissolution Profile of (F3) core tablet 342 mg in pH 6.8 Buffer
Type USP Type - II (Paddle)
RPM 50
Temp 37oC ± 0.5˚C
Volume
900 ml
Media pH 6.8 Buffer
Method: HPLC
S.No
Time
(minutes) 
% Drug  Release
Reference product
Tablets 342mg
Formula -F3 ( core tablet
342mg strength)
1. 5 44 58
2. 10 86 86
3. 15 95 90
4. 20 97 91
5. 30 98 91
6. 45 98 90
7. 60 99 90
Dissimilarity factor & Similarity factor
f1 value = 7.94 f2 value = 56.72
Figure No: 5 Dissolution graph of (F3) in pH 6.8 Buffer
Observation
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Dissolution rate of trial F3 was found to be high when compared with the reference product.
Discussion
By increasing the disintegration time the release of drug in the initial time point can be controlled
and  hence  it  was  decided  to  a  trial,  the  drug  release  using  the  formula  with  the  reduced
disintegrants.
Formulation trial- F4
Table No: 23 Comparative Dissolution Profile of (F4) core tablet 342 mg in pH 6.8 Buffer
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ±
0.5˚C
Volume 900 ml
Media pH 6.8 Buffer
Method: HPLC
S.No
Time
(minutes) 
% Drug  Release
Reference product
Tablet 342 mg
Formula F4 (core tablet 342
mg strength)
1. 5 44 48
2. 10 86 82
3. 15 95 91
4. 20 97 93
5. 30 98 94
6. 45 98 95
7. 60  99 98
f1 value = 3.49
Dissimilarity factor & Similarity factor
f2 value = 71.88
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Figure No: 6 Dissolution graph of (F4) core tablet 342 mg strength in pH 6.8 Buffer
Discussion 
The above results of drug release were found to be comparable with that of Reference product. It 
is also confirmed by the dissimilarity factor and similarity factor.
As the results are of core tablets was satisfactory, it was decided to coat the tablets and study the 
dissolution profile.
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Table No: 24 Comparative Dissolution Profile of (F4) Film coated tablets 342 mg in pH 6.8 
Buffer
Type USP Type - II (Paddle)
RPM 50
Temp 37oC ± 0.5˚C
Volume 900 ml
Media pH 6.8 Buffer
Method: HPLC
S.No
Time
(minutes) 
% Drug  Release
Formula F4
(Film coated tablets
342 mg)
1. 5 44 40
2. 10 86 81
3. 15 95 87
4. 20 97 91
5. 30 98 93
6. 45 98 94
7. 60 99 94
Dissimilarity factor & Similarity factor 
f1 value = 6.00 f2 value = 64.22
Figure No: 7 Dissolution graph of (F4) Film coated tablets 342 mg in pH 6.8 Buffer
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Discussion 
The  dissolution  profiling  of  coated  tablets  showed  comparable  with  the  Reference  product.
Based on the results of this trial, it was decided to take a reproducibility batch.
Formulation trial- F5 (Reproducibility batch)
Table No: 25 Comparative Dissolution Profile of (F5) Film coated tablets 342 mg in pH 6.8
Buffer
Type USP Type - II (Paddle)
RPM 50
Temp 37oC ± 0.5˚C
Volume 900 ml
Media pH 6.8 Buffer
S.NoHPL
C
Method: Time (minutes) 
% Drug
Release
Reference product Tablets 25mg                           
44 40
2. 10 86 84
3. 15 95 99
4. 20 97 100
5. 30 98 101
6. 45 98 101
7. 60 99 101
Dissimila
rity factor
&
Similarity
factor
f1 value = 3.40
f2 value = 75.00
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Figure No: 8 Dissolution graph of (F5) in pH 6.8 Buffer
Observation
The reproducibility batch showed comparable dissolution profiling with the reference product.
Conclusion
From the above trial it was confirmed that Test and Reference product dissolution profile were 
similar as the Formulation trial- F4. Hence finally Scale batch was planned.
SCALE UP BATCH
Formulation trial- F6
The scale-up batch was performed for dissolution in all 3 media as follows
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Table No: 26 Comparative Dissolution Profile of (F6) Film coated tablets 342 mg in Purified
water
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ±
0.5˚C
Volume 900 ml
Media Purified water
Method: HPLC
S.No
Time
(minutes)
% Drug  Release
Reference product
Tablets 342mg
Formula F6
(Film coated tablets 342 mg)
1. 5 44 45
2. 10 86 84
3. 15 95 92
4. 20 97 94
5. 30 98 94
6. 45 98 95
7. 60 99 100
f1 value = 2.76
Dissimilarity factor & Similarity factor
f2 value = 77.62
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Figure No: 9 Dissolution graph of (F6) in Purified water
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Table No: 28 Comparative Dissolution Profile of (F6) Film coated tablets 342 mg in 0.1N HCl
Figure No: 10 Dissolution graph of (F6) in 0.1N HCl
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Type USP Type - II (Paddle)
RPM 50
Temp
37oC ± 0.5˚C
Volume 900 ml
Media 0.1N HCl
Method: HPLC
S.No
Time
(minutes) 
% Drug  Release
Reference product
Tablets 342mg
Formula F6
(Film coated tablets 342 mg)
1. 5 26 28
2. 10 67 65
3. 15 90 90
4. 20 95 100
5. 30 96 101
6. 45 98 101
7. 60 98 101
Dissimilarity factor & Similarity factor
f1 value = 3.51 f2 value = 74.00
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Table No: 28 Comparative Dissolution Profile of (F6) Film coated tablets 342 mg in pH 6.8
buffer
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ±
0.5˚C
Volume 900 ml
Media pH 6.8 Buffer
Method: HPLC
S.No
Time
(minutes)
% Drug  Release
Reference
product Tablets
342mg 
Formula F6
(Film coated tablets 342 mg)
1. 5 40 47
2. 10 82 89
3. 15 96 97
4. 20 99 99
5. 30 100 100
6. 45 101 101
7. 60 102 102
f1 value = 1.38
Dissimilarity factor & Similarity factor
f2 value = 75.75
Figure No: 11 Dissolution graph of (F6) in pH 6.8 buffer
Formulation Development and Evaluation Of An Antipsychotic Drug As Immediate Release Tablets 73
                                                                         RESULTS AND DISSCUSION
Observation
 The dissolution profile of Test and Reference product was found to be similar. Also more than 
85 % of the drug is released at 15 minutes, in all the 3 media (Purified water, 0.1 N HCl, pH 
4.5buffer).
Discussion
The release profile was found to be satisfactory and comparable with that of Reference product.
This is also confirmed by dissimilarity factor and similarity factor in all the dissolution media.
Hence it was decided to pack the tablets in the proposed packaging and charge for stability.
Packing profile
The coated tablets were packed in PVC/PVDC blisters and loaded for stability.
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Ibuprofen lysine 684mg strength:
Table No: 29 Characteristics of the Formulation trial – F8, F9, F10 & F11 blend
Among the formulation trials , F7 trial were found to be slightly coarser in nature. The remaining
trials showed comparative reproducibility.
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S.No PARAMETERS F7 F8
F9
(Reproducibility
batch)
F10
(Scale up
Batch)
1. Bulk density (g/ml) 0.47 0.46 0.47 0.48
2. Tapped density (g/ml) 0.59 0.57 0.57 0.57
3. Carr’s index (%) 20.34 19.29 17.54 15.78
4. Hausner’s ratio 1.26 1.23 1.21 1.18
5. Flow property Passable Fair Fair Good
PARTICLE SIZE DISTRIBUTION
Sieve Analysis
Cumulative % of drug release
F7 F8 F9 F10
1. # 40 mesh retention 30.00 28.00 27.00 27.00
2. # 60 mesh retention 55.00 43.00 44.00 45.00
3. # 80 mesh retention 68.00 56.00 58.00 58.00
4. # 100 mesh retention 79.00 74.00 75.00 74.00
5. # PAN 100.00 100.00 100.00 100.00
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CORE TABLETS
S.No PARAMETERS F7 F8
F9 
Finalized batch
F10
Scale up
batch
1.
Average Weight 
(mg)
792.33 790.88 791.56
791.33
2. Thickness (mm) 5.50 5.57 5.62 5.59
3. Hardness (N) 162 169           171 168
4. Friability (% w/w) 0.07 0.02 0.03
0.02
5.
Disintegration 
Time (min & sec)
8mins 01
sec-
8mins 43
sec
9mins 47
sec- 9mins
58 sec
8mins 57sec-
9mins 01 sec
8mins 47 sec-
9mins 23sec
COATED TABLETS
10 Thickness(mm) 6.1 6.48 6.54 6.51
12.
Disintegration time
(min & sec)
8 mins
50 sec- 9
mins 02
sec
9mins
55sec- 10
mins 03sec
9mins 04sec-
9mins 34 sec
9mins 16 sec-
10mins 3sec
Table No: 29 Parameters of the Formulation trial – F7, F8, F9 & F10
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DISSOLUTION PROFILES OF DOSE PROPORTIONAL STRENGTHS
Formulation trial – F7
Table No: 30 Dissolution profiles of (F7) in pH 6.8 buffer
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ±
0.5˚C
Volume 900 ml
Media 6.8 buffer
Method: HPLC
% Drug release in pH 6.8 buffer
Time in
minutes
Reference product Formulation trial – F7 (Core tablet)
684mg 684mg
5 27 30
10 72 61
15 90 81
20 95 86
30 97 93
45 96 94
60 98 96
Dissimilarity factor & Similarity factor
                    
684
mg
f1 
val
ue 
                                                                                              6.75
f2 value                                                                                            57.07
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Figure No: 12 Dissolution graph for (F7) Core tablet in pH 6.8 buffer
Observation
Dissolution rate of trial F7 was found to be lesser when compared with the reference product.
Disscussion
The drug release of this feasibility trial made and found releases less than the reference product.
so ,the next trail is do with change in the concentration of Sodium starch glycolate and Povidone.
Formulation Development and Evaluation Of An Antipsychotic Drug As Immediate Release Tablets  74
                                                                         RESULTS AND DISSCUSION
Formulation trial– F8
Table No: 31 Dissolution profiles of (F8) in pH 6.8 buffer
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ±
0.5˚C
Volume 900 ml
Media 6.8 buffer
Method: HPLC
% Drug release in pH 6.8 buffer
Time in
minute
s
Reference product Formulation trial – F8
684mg 684mg
5 27 29
10 72 65
15 90 86
20 95 89
30 97 92
45 96 95
60 98 96
Dissimilarity factor & Similarity factor
                 
684m
gf1 
value 
                                                                                         4.70
f2 value                                                                                         67.63
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Figure No: 13 Dissolution graph for (F8) in pH 6.8 buffer
Observation
The dissolution profile of all the dose proportionate strengths of formulation F-8 was comparable
with the reference product. Also more than 85% of drug released at 15 minute time points like
reference product. 
Disscussion
The dissolution profile of this batch was found to be satisfactory; hence a reproducibility batch 
was planned and executed using the same formula and process of this batch.
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Formulation trial – F9 
Table No: 32 Dissolution profiles of (F9) in pH 6.8 buffer
Type USP Type - II (Paddle)
RPM 50
Temp
37oC ±
0.5˚C
Volume 900 ml
Media 6.8 buffer
Method: HPLC
% Drug release in  pH 6.8 buffer
Time in
minutes
Reference product Formulation trial – F9
400mg 400mg
5 27 29
10 72 66
15 90 86
20 95 90
30 97 93
45 96 95
60 98 97
Dissimilarity factor & Similarity factor
f1 value                                                                                             4.0
f2 value                                                                                           70.60
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Figure No: 14 Dissolution graph for (F9) in  pH 6.8 buffer.
Observation
The results indicate that the dissolution profile of the two dose proportionate strengths of the
formulation trialF-9 was comparable and reproducible as the formulation trial F-8.
Discussion 
Hence it was planned to formulate a scale up batch and to charge it for stability study.
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SCALE UP BATCH
Formulation trial – F10
Table No: 33 Dissolution profiles of (F10) in Purified water
Type USP Type - II (Paddle)
RPM 50
Temp 37oC ± 0.5˚C 
Media900 ml
Volume Purified water
Method: HPLC
% Drug release in Purified water
Time in
minutes Reference product 
Formulation
trial – F10 
684mg 684mg
27 29
10 72 66
15 90 87
20 95 91
30 97 93
45 96 95
60 98 97
Dissimilarit
y factor &
Similarity
factor
f1 value                                                                                               3.65
f2 value                                                                                              72.39
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Figure No: 15 Dissolution graph for (F10) in Purified water
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DISSOLUTION PROFILE IN 0.1N HCl
Table No: 34 Dissolution profiles of (F10) in 0.1N HCl
Type USP Type - II (Paddle)
RPM 50
Temp 37oC ± 0.5˚C
Volume 900 ml
Media 0.1N HCl
Method: HPLC
% Drug release in 0.1N HCl
Time in
minutes
Reference product Formulation trial – F10 
400mg 400mg
5 27 30
10 72 66
15 89 86
20 94 91
30 96 93
45 98 97
60 98 98
Dissimilarity factor & Similarity factor
f1 value                                                                                             3.31
f2 value                                                                                            73.55
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Figure No: 16 Dissolution graph for (F10) in 0.1NHCl
DISSOLUTION PROFILE IN pH4.5 BUFFER
Table No: 35 Dissolution profiles of (F10) in pH 6.8 Buffer
Type USP Type - II (Paddle)
RPM 50
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Temp 37oC ± 0.5˚C
Volume 900 ml
Media pH 6.8 Buffer
Method: HPLC
Formulati
on trial –
F10 % Drug release in pH 6.8 Buffer
Reference 
product 
Time in
minutes
684mg 684mg
22 29
10 63 66
15 85 87
20 90 89
30 92 90
45 92 91
60 91 92
Dissimilar
ity factor
&
Similarity
factor
f1 value                                                                                            3.18
f2 value                                                                                           74.25
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Figure No: 17 Dissolution graph for (F10) in pH 6.8 Buffer
Observation
The dissolution profile of the test and reference product was comparable which is confirmed by 
Dissimilarity factor and similarity factors. Also more than 85% of drug released at 15 minutes 
time points like reference products in all the 3 media (Purified water, 0.1 N HCl, purified water).
Discussion 
As the dissolution profile in all the  3 media was found to be satisfactory, hence the tablets were
packed in PVC/PVDC blisters  and charged for stability study in both stress condition for 15
days &1month ( 50°C/90%RH) and 1, 2, 3 month’s at accelerated condition ( 40°C/ 75%RH).
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Table No: 36 Stability Studies of Ibuprufen lysine Tablets 342mg (Formulation trial-6)
Stability studies 50°C/90% & RH 40°C/75% RH  -F6  scale up batch(342 mg)
Parameters Initial Results
Description
 white in 
colour
 white in colour
50°C/ 90%
RH 15days
50°C/ 90%
RH 1M
40°C/75%
RH- 1M
40°C/75%
RH- 2 M
40°C/75%
RH- 3 M
Avg. wgt (mg) 403.56 404.01 403.98 402.89 401.99 403.45
Hardness(N) 143 142 146 145 143 144
Thickness(mm) 4.60 4.69 4.59 4.58 4.60 4.59
Disintegration 
time(min& sec)
7mins 31 sec- 
7mins 46sec
7mins 30sec-
7mins 55sec
7mins 
12sec- 
7mins 33 
sec
7mins 
03sec- 
7mins 
40sec
7mins 
27sec- 
7mins 51sec
7mins 01 
sec- 7mins 
34sec
DISSOLUTION
Time
(minutes) Initial
50°C/ 90% 
RH 15days
50°C/ 90%
RH 1M
40°C/75%
RH- 1M
40°C/75%
RH- 2 M
40°C/75%
RH- 3 M
5 47 46 45 44 45 46
10 89 88 82 82 79 81
15 97 98 88 89 86 90
20 99 102 93 95 98 99
30 100 99 97 97 100 100
45 101 98 99 99 96 95
60 102 99 98 100 102 99
Assay 99-102% 99.33 98.87 99.84 100.03 101.00
Related substances by HPLC (%)
Known impurity NMT 0.2% 0.04 0.02 0.04 0.05 0.03
Unknown 
Impurity
NMT 0.15% 0.02 0.03 0.06 0.02 0.05
Total Impurity NMT 1.0 % 0.08 0.07 0.11 0.09 0.09
Figure No: 18 Stability Studies graph of Ibuprufen lysine Tablets 342mg (Formulation trial-6)
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Table No: 37 Stability Studies of Ibuprufen lysine Tablets 342mg (Formulation trial-10)
Stability studies 50°C/90% & RH 40°C/75% RH  -F10  scale up batch(684 mg)
Parameters Initial Results
Description
Almost white 
in colour
Almost white in colour
50°C/ 90%
RH 15days
50°C/ 90%
RH 1M
40°C/75%
RH- 1M
40°C/75%
RH- 2 M
40°C/75%
RH- 3 M
Avg. wgt (mg) 817.65 818.54 816.5 817.6 818.02 817.25
Hardness(N) 189 188 190 189 189 190
Thickness(mm) 6.51 6.47 6.52 6.51 6.49 6.47
Disintegration 
time(min& sec)
9mins 16 sec-
10mins 3sec
9mins 08 
sec- 9mins 
56sec
9mins 
17sec- 
10mins 
01sec
9mins 21 
sec- 10mins
02 sec
9mins 
45sec- 
10mins 04 
sec
9mins 15sec-
10mins 
05sec
Dissolution
Time
(minutes) Initial
50°C/ 90% 
RH 15days
50°C/ 90%
RH 1M
40°C/75%
RH- 1M
40°C/75%
RH- 2 M
40°C/75%
RH- 3 M
5 29 30 28 29 28 29
10 66 59 65 65 64 66
15 87 85 87 87 88 89
20 91 92 92 91 90 93
30 93 95 94 93 94 95
45 95 94 95 95 96 97
60 97 98 97 97 98 99
Assay 99-104% 99 101 102 99 103
Related substances by HPLC (%)
Known impurity NMT 0.2% 0.03 0.02 0.04 0.04 0.03
Unknown 
Impurity
NMT 0.15% 0.02 0.02 0.03 0.03 0.02
Total Impurity NMT 1.0 % 0.08 0.07 0.11 0.09 0.09
Observation and Discussion:
All  the  results  were  found  to  be  satisfactory  and  within  the  specified  limit.  There  were  no
significant changes after the 1 month, 2 months and 3 months study, further the stability studies
Formulation Development and Evaluation Of An Antipsychotic Drug As Immediate Release Tablets  87
                                                                         RESULTS AND DISSCUSION
will be performed and will be evaluated for the confirmation to achieve the specifications of the
reference product.
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CONCLUSION
7. CONCLUSION
The  Dissertation  work  entitled,  “Formulation  Development  and
Evaluation  of  NSAID’s  tablets”  was  carried  out  for  the  optimization  of  the
formulation  to  meet  the  quality  standards  with  regards  to  API,  excipients,
manufacturing process and finished product.
Drug-excipient  compatibility  studies  were  carried  out  and  the  results
showed  that  there  was  no  physical  and  chemical  change  in  the  API.  This
indicated  that,  the  drug  was  compatible  with  the  formulation  components.
Povidone k30, sodium starch glycollate and magnesium stearate were selected
as inactive excipients for the lab scale development.
The Prototype formulations were developed (F1-F10) and the formulation trial-
F6 of 342 mg strength  and the  formulation trial-F10 of 684 mg strength  the
invitro drug release profile was  optimized   to the Innovator product and it is
subjected to further studies.
The finalized batch, Confirmatory and scale up  formulation’s was taken for
stability studies as per the ICH Guidelines, all  batch were packed in HDPE
container and charged at  50°C/ 90% RH for the period of 15 days & 1M and
40°C/75% RH for  the  period of   1M, 2M and 3M. The results  were  found
satisfactory and it complies the satisfactions.
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SUMMARY
SUMMARY
Among the various routes of drug delivery system, Oral route is the oldest and
most common route of drug administration. In oral administration, tablet is one
of  the  most  preferred  dosage  forms  because  of  its  ease  of  manufacturing,
convenience in administration, accurate dosing and higher stability compared
with oral liquids.
The  project work entitled “Formulation Development and Evaluation of Anti
inflammatory drug  as Immediate Release Tablets” was carried out in the study.
The study was mainly focused on the optimization of the formulation to meet
the  reference  product  characteristics,  based  on  the  excipients  of  reference
product,  the excipients were selected for Drug Excipient  compatibility study
trials.  The binary mixtures were filled in  vials and closed with bromo butyl
rubber  stoppers  & crimped  with  tear  off  clear  lacquer  aluminum seals  and
charged at 50°C/90% RH and 40°C/75% RH conditions. All the excipients used
in the Drug-Excipients compatibility study were found to be compatible with
API.
The  development  was  started  by  using  direct  compression  technique  In
formulation trial-F3 (342 mg) was found that the drug release was more about
20% on comparing the reference product, at initial time point(5th minute). Hence
a  next  formulation  trial-F4  was  planned  to  reduce  the  drug  release.  The
formulation trial-F4 was  formulated using sodium starch glycolate. This gave
satisfactory  and  comparable  dissolution  profile  with  reference  product
(Reference  Products).  Hence  a  reproducibility  batch  (formulation  trial-F5)
followed by scale-up batch (formulation trial-F6) was formulated.
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The scale-up batch (formulation trial-F6) dissolution results in other media was
also found to be comparable and more than 85% of drug released at 15 minute
time points like reference product.   
Further the 684 mg strength started in  by direct compression technique method
was  adopted  (formulation  trial-F7).The  drug  release  profile  of  all  the  dose
proportionate strength (formulation trial-F7) was found to be similar, but found
to release  less  than  85% of drug at  15  minutes  on comparing  the  reference
products. Hence the next formulation trial (formulation trial-F8) was formulated
with povidone k30 and sodium starch glycolate concentration to reduce the drug
release at the initial time points.
The formulation trial-F8 gave a satisfactory dissolution results with more than
85% of drug release at 15 minute time points and a comparable drug release
profile  on  comparing  the  reference  products.  Based  on  this  trial,  a
reproducibility batch (formulation trial-F9) and a scale-up batch (formulation
trial-F10) was formulated which showed a satisfactory and similar drug release
profile as that of formulation trial-F8. The finalized formulations evaluated for
physical  characteristics  and  chemical  characteristics  were  found  to  be
satisfactory and comparable with the reference products.
The formulation trial-F6 of 342 mg strength  and the  formulation trial-F10 of
684 mg strength was taken for stability studies as per the ICH Guidelines, all
batch were packed in PVC/PVDC blisters and charged at 50°C/ 90% RH for the
period of 15 days & 1M and  40°C/75% RH for the period of  1M, 2M and 3M.
The  15  days  and  1  month  stability  data  at  stressed  condition  showed  no
characteristic changes when compared to the initial results which indicate the
product is stable. The 1 month, 2 month and 3 month stability at accelerated
condition was also found to be within the specified limits.
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